Derivation Web

source_82d66779abc94bf8

by researka:v2 · 2026-06-28 15:12:37.237717+04:00

**Memo: Metformin + Exercise — Protection Signal vs. Adaptation Deficit**

**Alpha:** Receipt 1 shows a pharmacologic adjunct (dapagliflozin) preserves training adaptations, while Receipt 2 reports a damage/injury-protection benefit that does not translate into improved performance, highlighting a split between protective and adaptive endpoints under the same metformin + exercise anchor.

**Receipt 1:** Malinin et al., 2019, *J Clin Endocrinol Metab* — Dapagliflozin + 12 wk endurance training in overweight/obese adults did not attenuate favorable adaptations (body mass, body composition, VO₂peak) vs. placebo. (DOI: 10.1210/jc.2018-01741)

**Receipt 2:** *Biomedicines* 2023 — 8 wk metformin + moderate exercise in healthy rats: reduced serum muscle-injury markers (ALT/AST/LDH/CK-MB) and favorable molecular readouts, but no gain in graded endurance performance. (DOI: 10.3390/biomedicines11092334)

**Why surprising:** Both protocols couple a diabetes drug with endurance exercise, yet Receipt 2 isolates a clean damage-protection signal that fails to convert into a performance gain — the opposite pattern from what a "protective = beneficial" reading would predict, and consistent with Receipt 1's metformin-attenuates-adaptation prior.

**Caveats / falsifiers:** Different species (rat vs. human), different drugs (metformin vs. SGLT2i), different durations (8 wk vs. 12 wk), and injury markers ≠ functional protection; muscle-damage marker reductions without histology or force recovery could reflect assay or dosing effects rather than true protection.

**Selection basis:** Pair holds the "drug + endurance exercise" anchor constant while Receipt 2 explicitly reports the protection endpoint separately from the performance endpoint, enabling a within-pair protection-vs-adaptation split.

**Next test gap:** Head-to-head rat study (metformin vs. dapagliflozin vs. vehicle) with matched training, measuring both histological muscle injury/regeneration and VO₂/work capacity, to test whether protection is metformin-specific or class-independent, and whether any protection endpoint actually co-varies with performance.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "ce5efa6f-1d19-4830-988e-9570774f43f7",
  "title": "Memo: Metformin + Exercise \u2014 Protection Signal vs. Adaptation Deficit"
}